Use of cis-bis-neodecanoato-trans-R,R-1, 2-diaminocyclohexane platinum (II), a liposomal cisplatin analogue, in cats with oral squamous cell carcinoma

Leslie E. Fox, Robert C. Rosenthal, Robert R. King, Paula B. Levine, David M. Vail, Stuart C. Helfand, E. Gregory MacEwen, Roman Perez-Soler, Maron Calderwood-Mays, Ilene D. Kurzman

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Objective: To determine clinical response and toxic effects of cis-bis- neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) (L-NDDP) administered IV at escalating doses to cats with oral squamous cell carcinoma (SCC). Animals: 18 cats with oral SCC. Procedure: Cats that failed to respond to conventional treatment or had nonresectable tumors were included. Data included a CBC, serum biochemical analyses, urinalysis, cytologic examination of a fine-needle aspirate of enlarged lymph nodes, and thoracic and oral radiographs for clinical staging. A starting dose (75 to 100 mg/m2 of L- NDDP) was administered IV. At 21-day intervals, subsequent doses increased by the rate of 5 or 10 mg/m2. Response was evaluated every 21 days by tumor measurement and thoracic radiography. Quality of life was assessed by owners, using a performance status questionnaire. Results: On average, cats received 2 treatments. Toxicoses included an intermittent, acute anaphylactoid- parasympathomimetic reaction, lethargy or sedation (≤ 24 hours), inappetence or signs of depression (≤ 72 hours), mild to moderate increase in hepatic enzyme activity, and melena. Pulmonary, renal, or hematopoietic abnormalities were not evident. Performance status surveys indicated normal behavior and grooming or decreased activity and self-care (19/20 assessments), ate well with or without assistance (15/20), and did not lose weight (15/20). Median survival time was 59.8 days (mean, 54.1 days). Conclusions and Clinical Relevance: L-NDDP was ineffective for treatment of cats with oral SCC. None of the cats had a complete or partial remission. Acute toxicoses and poor therapeutic response limit therapeutic usefulness of L-NDDP in cats, unless dosage, frequency, and administration procedures can be improved.

Original languageEnglish (US)
Pages (from-to)791-795
Number of pages5
JournalAmerican Journal of Veterinary Research
Volume61
Issue number7
StatePublished - Jul 2000
Externally publishedYes

Fingerprint

platinum
cisplatin
squamous cell carcinoma
Cisplatin
Squamous Cell Carcinoma
mouth
Cats
cats
chest
dosage
poisoning
parasympathomimetics
Parasympathomimetics
Thoracic Radiography
Melena
Therapeutics
Grooming
therapeutics
Lethargy
neoplasms

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Fox, L. E., Rosenthal, R. C., King, R. R., Levine, P. B., Vail, D. M., Helfand, S. C., ... Kurzman, I. D. (2000). Use of cis-bis-neodecanoato-trans-R,R-1, 2-diaminocyclohexane platinum (II), a liposomal cisplatin analogue, in cats with oral squamous cell carcinoma. American Journal of Veterinary Research, 61(7), 791-795.

Use of cis-bis-neodecanoato-trans-R,R-1, 2-diaminocyclohexane platinum (II), a liposomal cisplatin analogue, in cats with oral squamous cell carcinoma. / Fox, Leslie E.; Rosenthal, Robert C.; King, Robert R.; Levine, Paula B.; Vail, David M.; Helfand, Stuart C.; MacEwen, E. Gregory; Perez-Soler, Roman; Calderwood-Mays, Maron; Kurzman, Ilene D.

In: American Journal of Veterinary Research, Vol. 61, No. 7, 07.2000, p. 791-795.

Research output: Contribution to journalArticle

Fox, LE, Rosenthal, RC, King, RR, Levine, PB, Vail, DM, Helfand, SC, MacEwen, EG, Perez-Soler, R, Calderwood-Mays, M & Kurzman, ID 2000, 'Use of cis-bis-neodecanoato-trans-R,R-1, 2-diaminocyclohexane platinum (II), a liposomal cisplatin analogue, in cats with oral squamous cell carcinoma', American Journal of Veterinary Research, vol. 61, no. 7, pp. 791-795.
Fox, Leslie E. ; Rosenthal, Robert C. ; King, Robert R. ; Levine, Paula B. ; Vail, David M. ; Helfand, Stuart C. ; MacEwen, E. Gregory ; Perez-Soler, Roman ; Calderwood-Mays, Maron ; Kurzman, Ilene D. / Use of cis-bis-neodecanoato-trans-R,R-1, 2-diaminocyclohexane platinum (II), a liposomal cisplatin analogue, in cats with oral squamous cell carcinoma. In: American Journal of Veterinary Research. 2000 ; Vol. 61, No. 7. pp. 791-795.
@article{26b2e11b354649e09103ac17264b943f,
title = "Use of cis-bis-neodecanoato-trans-R,R-1, 2-diaminocyclohexane platinum (II), a liposomal cisplatin analogue, in cats with oral squamous cell carcinoma",
abstract = "Objective: To determine clinical response and toxic effects of cis-bis- neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) (L-NDDP) administered IV at escalating doses to cats with oral squamous cell carcinoma (SCC). Animals: 18 cats with oral SCC. Procedure: Cats that failed to respond to conventional treatment or had nonresectable tumors were included. Data included a CBC, serum biochemical analyses, urinalysis, cytologic examination of a fine-needle aspirate of enlarged lymph nodes, and thoracic and oral radiographs for clinical staging. A starting dose (75 to 100 mg/m2 of L- NDDP) was administered IV. At 21-day intervals, subsequent doses increased by the rate of 5 or 10 mg/m2. Response was evaluated every 21 days by tumor measurement and thoracic radiography. Quality of life was assessed by owners, using a performance status questionnaire. Results: On average, cats received 2 treatments. Toxicoses included an intermittent, acute anaphylactoid- parasympathomimetic reaction, lethargy or sedation (≤ 24 hours), inappetence or signs of depression (≤ 72 hours), mild to moderate increase in hepatic enzyme activity, and melena. Pulmonary, renal, or hematopoietic abnormalities were not evident. Performance status surveys indicated normal behavior and grooming or decreased activity and self-care (19/20 assessments), ate well with or without assistance (15/20), and did not lose weight (15/20). Median survival time was 59.8 days (mean, 54.1 days). Conclusions and Clinical Relevance: L-NDDP was ineffective for treatment of cats with oral SCC. None of the cats had a complete or partial remission. Acute toxicoses and poor therapeutic response limit therapeutic usefulness of L-NDDP in cats, unless dosage, frequency, and administration procedures can be improved.",
author = "Fox, {Leslie E.} and Rosenthal, {Robert C.} and King, {Robert R.} and Levine, {Paula B.} and Vail, {David M.} and Helfand, {Stuart C.} and MacEwen, {E. Gregory} and Roman Perez-Soler and Maron Calderwood-Mays and Kurzman, {Ilene D.}",
year = "2000",
month = "7",
language = "English (US)",
volume = "61",
pages = "791--795",
journal = "American Journal of Veterinary Research",
issn = "0002-9645",
publisher = "American Veterinary Medical Association",
number = "7",

}

TY - JOUR

T1 - Use of cis-bis-neodecanoato-trans-R,R-1, 2-diaminocyclohexane platinum (II), a liposomal cisplatin analogue, in cats with oral squamous cell carcinoma

AU - Fox, Leslie E.

AU - Rosenthal, Robert C.

AU - King, Robert R.

AU - Levine, Paula B.

AU - Vail, David M.

AU - Helfand, Stuart C.

AU - MacEwen, E. Gregory

AU - Perez-Soler, Roman

AU - Calderwood-Mays, Maron

AU - Kurzman, Ilene D.

PY - 2000/7

Y1 - 2000/7

N2 - Objective: To determine clinical response and toxic effects of cis-bis- neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) (L-NDDP) administered IV at escalating doses to cats with oral squamous cell carcinoma (SCC). Animals: 18 cats with oral SCC. Procedure: Cats that failed to respond to conventional treatment or had nonresectable tumors were included. Data included a CBC, serum biochemical analyses, urinalysis, cytologic examination of a fine-needle aspirate of enlarged lymph nodes, and thoracic and oral radiographs for clinical staging. A starting dose (75 to 100 mg/m2 of L- NDDP) was administered IV. At 21-day intervals, subsequent doses increased by the rate of 5 or 10 mg/m2. Response was evaluated every 21 days by tumor measurement and thoracic radiography. Quality of life was assessed by owners, using a performance status questionnaire. Results: On average, cats received 2 treatments. Toxicoses included an intermittent, acute anaphylactoid- parasympathomimetic reaction, lethargy or sedation (≤ 24 hours), inappetence or signs of depression (≤ 72 hours), mild to moderate increase in hepatic enzyme activity, and melena. Pulmonary, renal, or hematopoietic abnormalities were not evident. Performance status surveys indicated normal behavior and grooming or decreased activity and self-care (19/20 assessments), ate well with or without assistance (15/20), and did not lose weight (15/20). Median survival time was 59.8 days (mean, 54.1 days). Conclusions and Clinical Relevance: L-NDDP was ineffective for treatment of cats with oral SCC. None of the cats had a complete or partial remission. Acute toxicoses and poor therapeutic response limit therapeutic usefulness of L-NDDP in cats, unless dosage, frequency, and administration procedures can be improved.

AB - Objective: To determine clinical response and toxic effects of cis-bis- neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) (L-NDDP) administered IV at escalating doses to cats with oral squamous cell carcinoma (SCC). Animals: 18 cats with oral SCC. Procedure: Cats that failed to respond to conventional treatment or had nonresectable tumors were included. Data included a CBC, serum biochemical analyses, urinalysis, cytologic examination of a fine-needle aspirate of enlarged lymph nodes, and thoracic and oral radiographs for clinical staging. A starting dose (75 to 100 mg/m2 of L- NDDP) was administered IV. At 21-day intervals, subsequent doses increased by the rate of 5 or 10 mg/m2. Response was evaluated every 21 days by tumor measurement and thoracic radiography. Quality of life was assessed by owners, using a performance status questionnaire. Results: On average, cats received 2 treatments. Toxicoses included an intermittent, acute anaphylactoid- parasympathomimetic reaction, lethargy or sedation (≤ 24 hours), inappetence or signs of depression (≤ 72 hours), mild to moderate increase in hepatic enzyme activity, and melena. Pulmonary, renal, or hematopoietic abnormalities were not evident. Performance status surveys indicated normal behavior and grooming or decreased activity and self-care (19/20 assessments), ate well with or without assistance (15/20), and did not lose weight (15/20). Median survival time was 59.8 days (mean, 54.1 days). Conclusions and Clinical Relevance: L-NDDP was ineffective for treatment of cats with oral SCC. None of the cats had a complete or partial remission. Acute toxicoses and poor therapeutic response limit therapeutic usefulness of L-NDDP in cats, unless dosage, frequency, and administration procedures can be improved.

UR - http://www.scopus.com/inward/record.url?scp=0033932061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033932061&partnerID=8YFLogxK

M3 - Article

C2 - 10895902

AN - SCOPUS:0033932061

VL - 61

SP - 791

EP - 795

JO - American Journal of Veterinary Research

JF - American Journal of Veterinary Research

SN - 0002-9645

IS - 7

ER -